Bone mineral density in patients taking H2-receptor antagonist
Bone mineral density in patients taking H2-receptor antagonist
复制标题
DOI：
10.1007/s002239900431
复制
发表时间：
1998-04-01
影响因子：
4.2
通讯作者：
Kitano, S
中科院分区：
文献类型：
--
作者：
Adachi, Y;Shiota, E;Kitano, S
骨质疏松症是胃切除术后常见的临床疾病。在胃切除术患者中，胃酸减少可能与钙吸收受损有关。本研究旨在确定长期使用h -2受体拮抗剂（HRA）的患者是否有明显的骨矿物质密度（BMD）降低。对33例服用西咪替丁、雷尼替丁或法莫替丁2年以上的患者进行分析。我们使用双能x射线吸收仪（DXA）测量L2-L4的骨密度。骨质疏松症（骨密度小于0.70 g/cm(2)）仅在3例（9%）患者中发现。与健康对照相比，年龄和性别匹配的骨密度范围为74.4% ~ 132.9%，平均为97.0%，且不受使用HRA时间（5年以上）的影响。虽然不同HRA的年龄和性别匹配的骨密度不同（西咪替丁为98.6%，雷尼替丁为101.3%，法莫替丁为85.5%），但经多因素分析，骨密度与药物类型的关系不显著。这些结果表明，长期使用HRA对骨密度的影响不大，并提示胃酸降低并不一定与胃切除术后骨质疏松有关。
Osteoporosis after,gastrectomy is a common clinical disorder. In gastrectomized patients, decreased gastric acidity may be associated with impaired calcium absorption. This study was undertaken to determine whether patients with chronic use of H-2-receptor antagonists (HRA) had demonstrable decreases in bone mineral density (BMD). Thirty-three patients taking cimetidine, ranitidine, or famotidine for more than 2 years were analyzed. We measured BMD of L2-L4 using dual energy X-ray absorptiometry (DXA). Osteoporosis (BMD less than 0.70 g/cm(2)) was found only in three patients (9%). As compared with healthy controls, age-and sex-matched BMD ranged from 74.4% to 132.9%, with a mean of 97.0%, and was not influenced by the period of HRA use (5 years or more). Although the age-and sex-matched BMD was different among the kinds of HRA (98.6% for cimetidine, 101.3% for ranitidine, and 85.5% for famotidine), the relationship between the BMD and type of drug was not significant by multivariate analysis. These results indicate that chronic use of HRA has little influence on the degree of BMD, and suggest that decreased gastric acidity is not always associated with osteoporosis after gastrectomy.